Radius Health announced a definitive agreement to acquire the global development and commercialization rights to Benuvia Therapeutics (Benuvia) synthetic cannabidiol oral solution (RAD011).
Harmony Biosciences announced the first patient has been enrolled in a Phase 2 trial evaluating the safety and efficacy of pitolisant for the treatment of excessive daytime sleepiness (EDS) and other key symptoms in patients with Prader-Willi Syndrome.